Skip to main content

Advertisement

SpringerLink
Log in

Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

The study is about the regulatory effects of estrogen and parathyroid hormone (PTH) on sclerostin, a protein that inhibits the Wnt/β-catenin pathway. The results indicate that estrogen may down-regulate sclerostin expression and that estrogen displays synergistic action with PTH. These results provide a new perspective on the relationship between estrogen and bone.

Purpose

To investigate whether estrogen can down-regulate SOST and MEF2 (myocyte enhancer factor 2) expression and whether co-treatment with estrogen and PTH has a stronger effect on suppressing SOST than PTH applied alone in ovariectomized rats.

Methods

Forty-three-month-old virgin female Sprague–Dawley (SD) rats were ovariectomized and divided into four groups (n = 10). Another ten age-matched rats received sham operations as controls. After allowing 8 weeks for the development of vertebral osteopenia, the rats were administered the drug intervention. For this intervention, the estrogen group was subcutaneously injected with 17β-estradiol at 25 μg/kg body weight, the PTH group was injected with 80 μg/kg synthetic human PTH (1–34), and the co-treatment group was concurrently treated with PTH and estrogen at the above dosage. The OVX group and sham group were treated with vehicle. The drug treatment was conducted for 12 weeks. After the lumbar spine bone mineral density (BMD) was measured, the rats were sacrificed, and the lumbar spine and blood were collected for qPCR, Western blot, immunohistochemistry and other tests.

Results

Estrogen can down-regulate MEF2 and sclerostin expression, and co-treatment with estrogen and PTH has a stronger effect on suppressing MEF2 and SOST mRNA than PTH alone. The co-treatment group displayed slightly higher bone mass and biomechanical properties than the PTH group, but the differences were not significant.

Conclusions

Estrogen appears to be a regulator of sclerostin, and the effect may involve suppressing MEF2s. Combined treatment with PTH and estrogen is not more beneficial for vertebral bone mass and strength than treatment with PTH alone in ovariectomized rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Balemans W, Ebeling M, Patel N et al (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10(5):537–543

    Article  CAS  PubMed  Google Scholar 

  2. Brunkow ME, Gardner JC, Van Ness J et al (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68(3):577–589

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Staehling-Hampton K, Proll S, Paeper BW et al (2002) A 52-kb deletion in the SOST–MEOX1 intergenic region on 17q12–q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110(2):144–152

    Article  PubMed  Google Scholar 

  4. Balemans W, Patel N, Ebeling M et al (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39(2):91–97

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Winkler DG, Sutherland MK, Geoghegan JC et al (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22(23):6267–6276

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Poole KE, van Bezooijen RL, Loveridge N et al (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19(13):1842–1844

    CAS  PubMed  Google Scholar 

  7. van Bezooijen RL, Roelen BA, Visser A et al (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199(6):805–814

    Article  PubMed Central  PubMed  Google Scholar 

  8. Xu HG, Li ZR, Wang H et al (2013) Intermittent cyclic mechanical tension-induced down-regulation of ectonucleotide pyrophosphatase phosphodiesterase 1 gene expression is mainly dependent on TGF-beta1 in end-plate chondrocytes. Orthop Surg 5(1):40–45

    Article  PubMed  Google Scholar 

  9. Robling AG, Niziolek PJ, Baldridge LA et al (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283(9):5866–5875

    Article  CAS  PubMed  Google Scholar 

  10. Semenov M, Tamai K, He X (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280(29):26770–26775

    Article  CAS  PubMed  Google Scholar 

  11. Ott SM (2005) Sclerostin and Wnt signaling—the pathway to bone strength. J Clin Endocrinol Metab 90(12):6741–6743

    Article  PubMed  Google Scholar 

  12. Li X, Zhang Y, Kang H et al (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280(20):19883–19887

    Article  CAS  PubMed  Google Scholar 

  13. Hodsman AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26(5):688–703

    Article  CAS  PubMed  Google Scholar 

  14. Rubin MR, Bilezikian JP (2005) Parathyroid hormone as an anabolic skeletal therapy. Drugs 65(17):2481–2498

    Article  CAS  PubMed  Google Scholar 

  15. Bellido T, Ali AA, Gubrij I et al (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146(11):4577–4583

    Article  CAS  PubMed  Google Scholar 

  16. Silvestrini G, Ballanti P, Leopizzi M et al (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38(4):261–269

    Article  CAS  PubMed  Google Scholar 

  17. Sims NA (2010) Building bone with a SOST − PTH partnership. J Bone Miner Res 25(2):175–177

    Article  CAS  PubMed  Google Scholar 

  18. Kramer I, Keller H, Leupin O et al (2010) Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 21(4):237–244

    Article  CAS  PubMed  Google Scholar 

  19. Kramer I, Loots GG, Studer A et al (2010) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25(2):178–189

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Mirza FS, Padhi ID, Raisz LG et al (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95(4):1991–1997

    Article  PubMed Central  PubMed  Google Scholar 

  21. Drake MT, Srinivasan B, Modder UI et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056–5062

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Leupin O, Kramer I, Collette NM et al (2007) Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22(12):1957–1967

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Ardawi MS, Al-Kadi HA, Rouzi AA et al (2011) Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 26(12):2812–2822

    Article  CAS  PubMed  Google Scholar 

  24. Gatti D, Viapiana O, Adami S et al (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3):739–742

    Article  CAS  PubMed  Google Scholar 

  25. Gooi JH, Pompolo S, Karsdal MA et al (2010) Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 46(6):1486–1497

    Article  CAS  PubMed  Google Scholar 

  26. Shen V, Birchman R, Xu R et al (1995) Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. J Clin Invest 96(5):2331–2338

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Kobayashi S, Shimizu T, Mehdi R et al (1999) Advantages of concurrent use of anabolic and antiresorptive agents over single use of these agents in increasing trabecular bone volume, connectivity, and biomechanical competence of rat vertebrae. Bone 25(6):703–712

    Article  CAS  PubMed  Google Scholar 

  28. Shen V, Dempster DW, Mellish RW et al (1992) Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1–34) and 17 beta-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif Tissue Int 50(3):214–220

    Article  CAS  PubMed  Google Scholar 

  29. Qi H, Li M, Wronski TJ (1995) A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res 10(6):948–955

    Article  CAS  PubMed  Google Scholar 

  30. Shen V, Dempster DW, Birchman R et al (1993) Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest 91(6):2479–2487

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Wronski TJ, Cintron M, Doherty AL et al (1988) Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123(2):681–686

    Article  CAS  PubMed  Google Scholar 

  32. Zhao M, Kim YT, Yoon BS et al (2006) Expression profiling of cyclin B1 and D1 in cervical carcinoma. Exp Oncol 28(1):44–48

    CAS  PubMed  Google Scholar 

  33. Henslee AM, Spicer PP, Yoon DM et al (2011) Biodegradable composite scaffolds incorporating an intramedullary rod and delivering bone morphogenetic protein-2 for stabilization and bone regeneration in segmental long bone defects. Acta Biomater 7(10):3627–3637

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Garnero P, Sornay-Rendu E, Chapuy MC et al (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11(3):337–349

    Article  CAS  PubMed  Google Scholar 

  35. Canpolat S, Tug N, Seyran AD et al (2010) Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats. J Physiol Biochem 66(1):23–28

    Article  CAS  PubMed  Google Scholar 

  36. Riggs BL, Khosla S, Melton LR (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23(3):279–302

    Article  CAS  PubMed  Google Scholar 

  37. Jastrzebski S, Kalinowski J, Stolina M et al (2013) Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res 28(3):618–626

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Brand NJ (1997) Myocyte enhancer factor 2 (MEF2). Int J Biochem Cell Biol 29(12):1467–1470

    Article  CAS  PubMed  Google Scholar 

  39. Genetos DC, Toupadakis CA, Raheja LF et al (2010) Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem 110(2):457–467

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Gatti D, Viapiana O, Fracassi E et al (2012) Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 27(11):2259–2263

    Article  CAS  PubMed  Google Scholar 

  41. Finkelstein JS, Wyland JJ, Lee H et al (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95(4):1838–1845

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11(2):76–81

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (No. 81102607), the Key Technologies & Program of Tianjin (No. 13ZCZDSY01700 and 11ZCGYSY01800) and the Scientific and Technological Project of Tianjin Public Health Bureau (No. 11KG137 and No. 12KG120).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Tianjin Medical University General Hospital, 154, Anshan Street, Heping District, Tianjin, 300052, China

    H. B. Jia, X. L. Ma, J. T. Yu, R. Feng, L. Y. Xu, J. Wang & D. Xing

  2. Tianjin Hospital Heping Branch, Biomechanics Labs of Orthopedic Research Institute, 122, MuNan Street, Heping District, Tianjin, 300050, China

    H. B. Jia, J. X. Ma, X. L. Ma, S. W. Zhu & Y. Wang

Authors
  1. H. B. Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. X. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. L. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. T. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Y. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. W. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. L. Ma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jia, H., Ma, J., Ma, X. et al. Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats. Osteoporos Int 25, 2743–2754 (2014). https://doi.org/10.1007/s00198-014-2818-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-014-2818-y

Keywords

Search

Navigation